A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine whether reslizumab is more effective than
placebo in reducing the number of clinical asthma exacerbations (CAEs) in patients with
eosinophilic asthma.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.